Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Types of primary outcome measures used in all included randomised controlled trials

From: A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease

Primary outcome measure Frequency of use of primary outcome measure in randomised controlled trials in:
Alzheimer’s disease
(n = 83)
Parkinson’s disease (n = 44)
n % n %
Clinical outcome measure only 62 75 24 55
Clinical outcome measure and biomarker 6 7 4 9
Clinical outcome measure and time-to-event outcome 1 1 0 0
Biomarker only 12 15 5 11
Time-to-event outcome only 2 2 11 25
  1. There was insufficient information available about one unpublished trial’s [42] outcome measures to allow its classification